Previous 10 | Next 10 |
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and...
Gainers: Terns Pharmaceuticals (TERN) +6%. Puma Biotechnology (PBYI) +6%. Quantum-Si Incorporated (QSI) +5%. Sotherly Hotels (SOHO) +5%. Annexon (ANNX) +5%. Losers: Qutoutiao (QTT) -6%. View (VIEW) -5%. Clearside Biomedical (CLSD) -5%. Payoneer Global (PAYO) ...
Puma Biotechnology, Inc. (the Company) (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into a securities purchase agreement with Alan H Auerbach, the Company’s Chief Executive Officer, President and Chairman of the Board, as well as a fund of Athyrium C...
Puma Biotechnology recently reported its Q4 and full-year 2021 earnings that revealed a solid beat on EPS and revenue. The company reported $55.4M in total revenue for Q4 of 2021. NERLYNX net revenue came in at $51M for Q4, which was up from $43.4M in Q3 and $50M in Q4 of 2020. This t...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel discussion on breast cancer at Cowen’s 42 nd Annual Health Care Conference, whi...
Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%. ...
Puma Biotechnology, Inc. (PBYI) Q4 2021 Earnings Conference Call March 3, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President & CEO Jeff Ludwig - Chief Commercial Officer Maximo Nougues - CFO Conference Call Participants Edward ...
Shares of Puma Biotechnology (NASDAQ:PBYI) have raced 15% higher in post-market trading after posting Q4 2021 results that beat on the top and bottom lines. The company swung to a quarterly net gain of $4.2M from a net loss of $15M in the prior year period ($0.10 per share basic by ...
Puma Biotechnology press release (NASDAQ:PBYI): Q4 Non-GAAP EPS of $0.21 beats by $0.20. Revenue of $55.4M (+5.3% Y/Y) beats by $8.23M. Cash, equivalents, and marketable securities of $82.1 million, compared to cash, cash equivalents, and marketable securities of $93.4 million at December 31,...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 3, following release of its fourth quarter and full year 2021 financial results. The call may be accessed by dialing 1-877-709-8150 (do...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...